Flindr Labs SRL
4.2 FTEFlindr Labs reported total assets of 262,929 € at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Jun 2026), with 4.2 full-time equivalents.
The score of Flindr Labs shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Flindr Labs's annual accounts
| 2025 | |
|---|---|
| Net result | −591,098 € |
| Equity | −391,098 € |
| Cash | 39,260 € |
| EBITDA | −194,580 € |
| Total assets | 262,929 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
Flindr Labs's financial analysis
- Solvency-148.7%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Flindr Labs
Flindr Labs's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1014.117.578
- VAT number
- BE1014117578
- Peppol
- Registered · 0208:1014117578 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 25 Sep 2024
- Registered office
- 9052 Ghent
- Size
- Micro · 4.2 FTE
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Flindr Labs (SRL) has been based in Ghent since 2024, active in: manufacture of medicaments. For 2025, it reports a net loss of 591,098 € and equity of −391,098 €; its revenue is not published. With 4.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -148.7%, below the median of its sector (47.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Flindr Labs
Companies in the same business, of comparable size and area, outside its group.
- Pharmacosmedics Research and experimental development on natural sciences and engineering Knokke-Heist · balance sheet 289,301 €
- Ergotrics Research and experimental development on natural sciences and engineering Turnhout · balance sheet 376,384 €
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Intibio Manufacture of pharmaceutical preparations Bree · balance sheet 407,778 €
- Rodilo Manufacture of pharmaceutical preparations Liège · balance sheet 204,587 €
- Elkedonia Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet 228,425 €
- MY Health International Manufacture of basic pharmaceutical products Lummen · balance sheet €1.04m
Frequently asked questions about Flindr Labs
What is the revenue of Flindr Labs?
Flindr Labs files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Flindr Labs?
In Belgium, the VAT number is the company number prefixed with BE: BE1014117578 for Flindr Labs, if the company is VAT-registered. Its company number (CBE) is 1014.117.578.
Where is the registered office of Flindr Labs?
According to the CBE register, the registered office of Flindr Labs is in 9052 Ghent.
What is the equity of Flindr Labs?
At the close of the 2025 financial year, the equity of Flindr Labs amounts to -391,098 €, a solvency of -148.7% of total assets.
How many people work at Flindr Labs?
4.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Flindr Labs?
The register lists 3 active mandates at Flindr Labs. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Flindr Labs
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →